Dosage protocol · Bioregulators
Chonluten 20 mg
Typical daily range: 250–4,000 mcg once daily (gradual titration over 8–16 weeks).
- Reconstitute: Add 3.0 mL bacteriostatic water → 6.67 mg/mL concentration.
- Typical daily range: 250–4,000 mcg once daily (gradual titration over 8–16 weeks).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.67 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: refrigerate at 4 °C (39.2 °F) short‑term or freeze at −20 °C (−4 °F) long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Reconstitution
Chonluten dosage chart
| Week | Dose | Draw |
|---|---|---|
| Weeks 1–2 | 250 mcg0.25 mg | 3.75 units0.0375 mL |
| Weeks 3–4 | 500 mcg0.5 mg | 7.5 units0.075 mL |
| Weeks 5–6 | 1,000 mcg1 mg | 15 units0.15 mL |
| Weeks 7–8 | 1,500 mcg1.5 mg | 22.5 units0.225 mL |
| Weeks 9–10 | 2,000 mcg2 mg | 30 units0.30 mL |
| Weeks 11–12 | 3,000 mcg3 mg | 45 units0.45 mL |
| Weeks 13–14 | 4,000 mcg4 mg | 60 units0.60 mL |
| Weeks 15–16 | 4,000 mcg4 mg | 60 units0.60 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Chonluten is a short synthetic tripeptide made from glutamic acid, aspartic acid, and glycine, commonly written Glu-Asp-Gly or EDG. PubChem lists it as CID 194641, with molecular formula C11H17N3O8 and a molecular weight of about 319 g/mol.[1] It is sometimes referenced by the shorthand T-34. Like Cardiogen and Cartalax, it falls into the peptide bioregulator research category, and it is discussed mainly in relation to lung and bronchial biology because the sequence has been described as derived from bronchial epithelial cells — a description that establishes a research rationale, not a proven respiratory benefit.[2]
Benefits & side effects
No human adverse-event data exist for Chonluten because no clinical trials have been conducted. The in vitro study measured cell-signaling changes, not safety outcomes, so it cannot be used to infer that the compound is safe in people.[2] More broadly, therapeutic peptides can carry immunogenicity risks tied to manufacturing impurities, and unapproved or compounded peptide products carry additional risks of contamination or inaccurate potency.[12][14] Pregnancy, breastfeeding, pediatric use, and use by people with active respiratory or autoimmune disease are entirely unstudied for Chonluten specifically.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.